



Provincial Health Services Authority

Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca and according to acceptable standards of care

PROTOCOL CODE: MYBLDPRE

Page 1 of 2

Patient RevAid ID: _____

DOCTOR'S ORDERS		Ht _____ cm	Wt _____ kg	BSA _____ m ²
REMINDER: Please ensure drug allergies and previous bleomycin are documented on the Allergy & Alert Form				
DATE: _____		To be given: _____		Cycle #: _____
Date of Previous Cycle: _____				
Risk Category: <input type="checkbox"/> Female of Childbearing Potential (FCBP) Rx valid for 7 days				
Risk Category: <input type="checkbox"/> Male or Female of non-Childbearing Potential (NCBP)				
<input type="checkbox"/> Delay treatment _____ week(s)				
<input type="checkbox"/> CBC & Diff day of treatment				
Proceed with treatment for entire cycle as written, if within 96 hours of Day 1: ANC greater than or equal to 1.0 x 10⁹/L, platelets greater than or equal to 50 x 10⁹/L and eGFR or creatinine clearance as per protocol				
Dose modification for: <input type="checkbox"/> Hematology <input type="checkbox"/> Renal Function <input type="checkbox"/> Other Toxicity				
Proceed with treatment based on blood work from _____				
LENALIDOMIDE			Pharmacy Use for	
One cycle = 28 days			<u>Lenalidomide dispensing:</u>	
<input type="checkbox"/> lenalidomide* _____ mg PO daily, in the evening, on days 1 to 21 and off for 7 days			Part Fill # 1	
<input type="checkbox"/> lenalidomide* _____ mg PO _____			RevAid confirmation number: _____	
(*available as 25 mg, 20 mg, 15 mg, 10 mg, 5 mg, 2.5 mg capsules)			Lenalidomide lot number: _____	
*Note: Use one capsule strength for the total dose; there are cost implications as costing is per capsule and not weight based			Pharmacist counsel (initial): _____	
<input type="checkbox"/> FCBP dispense 21 capsules (1 cycle)			Part Fill # 2	
<input type="checkbox"/> For Male and Female NCBP:			RevAid confirmation number: _____	
MITTE: _____ capsules or _____ cycles . Maximum 63 capsules (3 cycles).			Lenalidomide lot number: _____	
Pharmacy to dispense one cycle at a time, maximum 3 cycles if needed.			Pharmacist counsel (initial): _____	
STEROID (select one)*			Part Fill # 3	
<input type="checkbox"/> dexamethasone <input type="checkbox"/> 40 mg or <input type="checkbox"/> 20 mg PO once weekly in the morning on Days _____ (write in) of each cycle			RevAid confirmation number: _____	
<input type="checkbox"/> dexamethasone _____ mg PO once weekly in the morning on Days _____ (write in) of each cycle			Lenalidomide lot number: _____	
<input type="checkbox"/> predniSONE _____ mg PO once weekly in the morning on Days _____ (write in) of each cycle			Pharmacist counsel (initial): _____	
<input type="checkbox"/> No Steroid			Part Fill # 3	
*Refer to Protocol for suggested dosing options			RevAid confirmation number: _____	
Physician to ensure DVT prophylaxis in place: <input type="checkbox"/> ASA, <input type="checkbox"/> Warfarin, <input type="checkbox"/> low molecular weight heparin, <input type="checkbox"/> direct oral anticoagulant or <input type="checkbox"/> none (select one)			Lenalidomide lot number: _____	
			Pharmacist counsel (initial): _____	
Special Instructions				
DOCTOR'S SIGNATURE:			SIGNATURE:	
Physician RevAid ID: _____			UC: _____	



Provincial Health Services Authority

Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca and according to acceptable standards of care

PROTOCOL CODE: MYBLDPRE

Page 2 of 2

DATE:	
TREATMENT: <ul style="list-style-type: none">A referral to the Leukemia/BMT Program of BC must be made at the start of the first cycle or shortly after for planning purposes.Per physician's clinical judgement, physician to ensure prophylaxis with valACYclovir 500 mg PO daily	
CYCLE # _____ (Cycles 1 to 6)	
bortezomib <input type="checkbox"/> 1.5 mg/m ² or <input type="checkbox"/> 1.3 mg/m ² or <input type="checkbox"/> 1 mg/m ² or <input type="checkbox"/> 0.7 mg/m ² or <input type="checkbox"/> 0.5 mg/m ² (select one) x BSA = _____ mg subcutaneous injection on Days 1, 8, 15, and 22	
RETURN APPOINTMENT ORDERS	
For Cycles 1 to 6, book chemo on Days 1, 8, 15, and 22 <input type="checkbox"/> Return in four weeks for Doctor and Cycle _____ <input type="checkbox"/> Last cycle. Return in _____ week(s)	
CBC & Diff, creatinine, urea, sodium, potassium, total bilirubin, ALT, alkaline phosphatase, calcium, albumin, LDH, random glucose, serum protein electrophoresis <u>and</u> serum free light chain levels every 4 weeks TSH every three months (i.e. prior to cycles 4, 7, 10, 13, 16 etc) <input type="checkbox"/> Urine protein electrophoresis every 4 weeks <input type="checkbox"/> Beta-2 microglobulin every 4 weeks <input type="checkbox"/> Immunoglobulin panel (IgA, IgG, IgM) every 4 weeks <input type="checkbox"/> CBC & Diff Days 8, 15, 22 <input type="checkbox"/> Creatinine, sodium, potassium Days 8, 15, 22 <input type="checkbox"/> Total bilirubin, ALT, alkaline phosphatase Days 8, 15, 22 <input type="checkbox"/> Random glucose Days 8, 15, 22 <input type="checkbox"/> Calcium, albumin Days 8, 15, 22 <input type="checkbox"/> Quantitative beta-hCG blood test for FCBP 7-14 days and 24 h prior to cycle 1 and every week for 4 weeks during cycle 1 <input type="checkbox"/> Quantitative beta-hCG blood test for FCBP, every 4 weeks, less than or equal to 7 days prior to the next cycle <input type="checkbox"/> HBV viral load prior to next cycle <input type="checkbox"/> Other tests: <input type="checkbox"/> Consults: <input type="checkbox"/> See general orders sheet for additional requests	
DOCTOR'S SIGNATURE:	SIGNATURE: UC: